The Cancer Standard Nobody Is Hitting — And the Hospital Lottery Behind It

The NHS has a 62-day cancer treatment target. It has not been met nationally in years. But the national number hides the real story: where you live changes your odds.

A few weeks ago I dropped my wife at Princess Royal Hospital in Telford.

The waiting room was full. I wasn’t surprised, and I wasn’t really annoyed — that’s the deal now. You go in expecting to wait.

I went to find the machine to pay for parking.

And I got lost.

Somewhere in the wrong corridor, away from where I was meant to be, I started thinking about the people who don’t get to leave after a few hours. The ones whose treatment does not start that day, or that week.

I thought about cancer, not because I know something special about oncology, but because it is the one condition where delay feels different. If the waiting room I had just walked out of was this full, what happens to someone who has been told they might have cancer?

Do they wait too?

Surely not.

Surely that is the one thing the system moves fast for.

I assumed it depended mainly on the type of cancer. Some cancers are aggressive. Some are caught early. Some need treatment within days. And it does depend on that.

But when I got home and pulled the data, I found it depends on something else too.

Something I did not expect.

It depends on which hospital trust your referral lands in.

What the 62-day standard actually is

Here’s the thing the NHS measures, in plain terms.

When your GP is worried enough to send you for urgent suspected cancer checks, the clock starts. From that referral to the start of your first treatment, no more than 62 days should pass.

Two months.

The official target is that 85% of patients should be treated inside that window.

Why 62 days? Because cancer does not wait. Two months is already a long time when something might be growing inside you, but it is the line the NHS drew as the outer edge of what is clinically acceptable for most cancers.

Miss it, and you are not just late on a form.

You are late on treatment.

That is the standard.

Now here is what is happening to it.

Zero out of eighteen

I looked at every month from October 2023 to March 2025 — eighteen months of England-wide data published by NHS England.

The 85% target was met in zero of those eighteen months.

I expected that, honestly. The 62-day standard has been missed for years. It is not new. So I looked for a gentler test.

In 2024, the NHS set itself an interim target — a stepping stone — of 70%.

An easier bar. One it set for itself to show progress on the way back to 85%.

It missed that too.

Zero out of eighteen months.

Across the whole period, the national average was 62.1%.

Not in one bad region. Not in one struggling specialty. Across England, for a year and a half, roughly four in ten cancer patients started treatment later than the standard says they should.

There is one thing worth saying in the NHS’s favour, because the data shows it and leaving it out would be dishonest: performance is slowly climbing.

It started around 58% in late 2023 and crept towards 67% by the end of 2024.

The direction is right.

But “improving” and “acceptable” are not the same word.

Even at its best month, the NHS did not come within 17 percentage points of its own full target.

When you add up every patient who waited longer than 62 days across those eighteen months, the number is 111,280.

That is not an abstract percentage.

That is roughly 6,000 people a month being told their cancer treatment will start late.

National 62-day trend line

The lottery

The national average of 62% is already bad.

But it is also a comfort blanket, because averages hide the people at the edges.

So I broke the data down by trust.

Every NHS hospital trust in England with a meaningful number of cancer patients, ranked by how often they hit the 62-day standard over the same eighteen months.

The best-performing trust was Calderdale and Huddersfield, at 87.3% — above the national target.

The worst was Mid and South Essex, at 39.1%.

Sit with that for a second.

That is a 48.2 percentage point gap.

In the best-performing trust, nearly nine in ten patients started treatment within 62 days. In the worst, fewer than four in ten did.

Same illness.

Same country.

Same NHS.

Same national standard that both are supposed to meet.

That is the lottery.

Not a metaphor. A measurable 48-point difference in your chance of timely cancer treatment, depending on which hospital trust your referral happens to land in.

Worst vs best trusts

And here is the part I genuinely did not expect.

The worst performers are not all small, struggling, underfunded trusts in forgotten corners.

Some are among the biggest names in the NHS.

University Hospitals Birmingham, one of the largest trusts in the country, sat at 40.0%.

Sheffield Teaching Hospitals sat at 42.0%.

Guy’s and St Thomas’, a flagship London trust, sat at 43.0%.

These are major teaching hospitals. Centres of excellence.

And on this measure, they are near the bottom.

Whatever is going wrong here, it is not simply about size, reputation, or whether a hospital is “good” in the way people usually mean it.

Cancer waiting times expose something more uncomfortable.

The places with the most resources can still be among the places where cancer patients wait the longest.

The hospital that serves my town

The trust that covers Telford, where I was standing in that corridor, is The Shrewsbury and Telford Hospital NHS Trust.

It came seventh from the bottom.

45.6%.

Over the eighteen months, 1,818 of its cancer patients started treatment later than the 62-day standard.

And there is a detail I learned that makes it more concrete.

The cancer pathway here is split across two towns. Princess Royal in Telford handles diagnostics and cancer surgery, but most radiotherapy and chemotherapy is handled at the Lingen Davies Centre in Shrewsbury, about seventeen miles away.

The clock does not stop for the drive.

I am not writing this to single out one trust.

I am writing it because it is mine, the one down the road, the one I would actually go to.

And that is the uncomfortable thing about a lottery.

Everyone is in it.

Including you.

Why I’m not just naming villains

It would be easy to stop here, point at the ten worst trusts, and call them the problem.

It would also be wrong.

Because a low percentage tells us the odds, but a high breach count tells us the number of people affected.

Both matter.

So I also looked at where the actual breaches happened, not just who had the worst rate, but which trusts had the most patients waiting longer than 62 days.

The ten highest-volume breach trusts accounted for about 21% of all breaches.

That is important.

It means this is not a story about a handful of failing hospitals dragging down an otherwise healthy system.

The other 79% is spread across the country, dozens and dozens of trusts, each carrying their share.

That is a harder story to tell than “here are the villains”.

But it is the true one.

And the true one is the only one worth publishing.

Highest breach volumes

What the data cannot tell us

The data does not tell me why each trust missed the standard.

It does not show the number of oncologists available that month. It does not show theatre capacity, diagnostic backlogs, scanner access, referral complexity, staffing gaps, patient choice, or how many people needed treatment across multiple sites.

So this is not a claim that one hospital cares more than another.

It is not a claim that the staff in one trust are working harder than the staff in another.

That would be unfair, and probably untrue.

What the data does show is simpler, and harder to ignore.

The same national standard is producing very different patient odds depending on where the referral lands.

That is the part we should not explain away.

What I’m left holding

I went into that hospital as a husband looking for a parking machine.

I came out with a question I could not shake:

What happens to the person with cancer?

Now I have an answer, and it is worse than I expected.

Most of them wait longer than they should.

And how much longer depends not only on what kind of cancer they have, but on which set of doors they walk through.

The 62-day standard exists because someone, once, decided that two months was the outer edge of acceptable when a life is on the line.

The NHS wrote that line itself.

For eighteen months straight, across England, it did not reach it, not even the easier version of it.

Cancer does not care which hospital you live near.

But the data shows your chance of timely treatment still does.

This analysis covers NHS England Cancer Waiting Times monthly statistics from October 2023 to March 2025 — eighteen months of provider-level data, filtered to the post-October 2023 standards framework for clean comparability. I excluded the England total row when ranking trusts and applied a minimum patient-volume threshold of 500 patients over the period, so that very small providers did not distort the extremes. The full pipeline was built in Python and Parquet using a Bronze → Silver → Gold structure.

GitHub: github.com/YusufIsmailayo

This is part of my NHS data project series, using public healthcare data to explore what national averages hide once you break them down by place, pathway, and patient impact.